Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Recruiting

Phase 2

Visugromab, Nivolumab & LenvatinibVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Sponsor:

CatalYm GmbH

Code:

NCT07219459

Conditions

Unresectable or Metastatic Hepatocellular Carcinoma

Child-Pugh A Hepatocellular Carcinoma

Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Visugromab RDE (recommended dose for expansion)

Nivolumab

Lenvatinib

Placebo Saline Infusion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-20. This information was provided to ClinicalTrials.gov by CatalYm GmbH on 2026-06-24.